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1. Introduction 
Gastro-esophageal reflux disease (GERD) is “a condition which develops when the reflux of 
stomach contents causes troublesome symptoms (i.e., at least two heartburn episodes per 
week) and/or complications” (Vakil et al 2006) and represents one of the fastest growing 
disease affecting the alimentary tract. Recently studies on the epidemiology of GERD 
demonstrating that GERD is a highly prevalent disorder with 10-20% of individuals affected 
in western civilization (Dent et al 2005). When GERD is defined as twice weekly reflux over 
several months, 10-20% of individuals in Western civilization are affected, which is 
significantly higher than in Asian population (5%)  (Bonatti et al 2008). In a large prospective 
American cohort study is reported that 25% of investigated individuals experienced 
nocturnal reflux symptoms  (Fass et al 2005). A recent population-based study demonstrated 
the prevalence of reflux symptoms to be 44% with 24% of individuals experiencing 
symptoms for two days or more per week. The prevalence of oesophagitis and Barrett’s 
oesophagus was 12% and 1.3% respectively, irrespective of symptoms  (Zagari et al 
2008).Thirty-three per cent of individuals with oesophagitis and 46% with Barrett’s 
oesophagus were asymptomatic. Severe GERD can lead to potentially avoidable 
complications including severe oesophagitis with scarring and stricture formation, Barrett’s 
esophagus and adenocarcinoma.When symptoms become frequent and severe enough to 
require regular medication, there is a significant impact on quality of life  (Ware et al 
1992).(QOL) 
2. Pathophysiology 
GERD results from failure of the reflux barrier. This barrier has three components: (1) an 
intra-abdominal esophagus of adequate length, (2) an extrinsic sphincter, the esophageal 
hiatus, and (3) an intrinsic sphincter, the lower esophageal sphincter (Bloom et al 2009). 
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Relaxation of the LES and crura are normal physiological processes occurring during 
swallowing and also during gas venting. Relaxations not initiated by a swallow are known 
as transient lower esophageal relaxations (TLESRs). Abnormal TLESRs have a greater 
crosssectional area at the gastro-oesophageal junction resulting in the reflux of gastric fluid 
in addition to gas. TLESRs probably account for 90% of reflux episodes. The TLESR reflex is 
initiated by tension receptors in the stomach and mediated by a vagovagal pathway via the 
brainstem leading to simultaneous relaxation of the crura, LES and inhibition of peristalsis 
(Pandolfino et al 2003). These responses are inhibited by gammaaminobutyric acid-B 
(GABA-B) receptor agonists, and thus may constitute a future therapeutic target. Hiatus 
hernias appear to increase the magnitude of reflux during TLESRs. Transient lower 
oesophageal relaxations appear to be less significant in more severe reflux esophagitis. A 
hypotensive LES, which allows high pressure gradients across the diaphragm, is probably 
responsible for more severe esophagitis (Barham et al 1995). Reflux occurs more 
frequently when the pressure in the LES is <10 mm Hg, and free reflux only occursif the 
LES pressure is <4 mm Hg (Kahrilas et al 1986; Dodds et al 1982). Factors which relax the 
LES, such as caffeine, fat, smoking, drugs (calcium channel antagonists and nitrates) and 
gastric distention, will increase the likelihood of reflux. The association of increased body 
mass index and GERD remains unclear (Hampel et al 2005; Pandolfino et al 2006). A 
recent study failed to demonstrate an increased risk of reflux symptoms or esophagitis in 
obese individuals. Acid in the distal oesophagus has been shown to be neutralised by 
saliva. Therefore any processes reducing saliva production results in a delay in acid 
neutralisation. Nocturnal reflux episodes are prolonged due to depressed salivation. Acid 
is cleared by oesophageal peristalsis. Therefore impaired distal esophageal peristalsis 
results in prolonged acid exposure to acid reflux episodes. This is apparent in both hiatus 
hernias and ulcerative oesophagitis where there is peristaltic dysfunction  (Kahrilas et al 
2006, Johnson et al 1980). 
3. Simptomatology 
Typical GERD symptoms—heartburn and regurgitation—reflect dysfunction of the reflux 
barrier. 
Dysphagia is a third, less specific, GERD symptom. It may be caused by GERD itself or 
stricture complicating GERD. GERD-related dysphagia must be differentiated from 
functional and mechanical dysphagia resulting from multiple other diseases that cause 
symptomatic esophageal obstruction. Atypical GERD symptoms are cough, asthma, 
laryngitis, sore throat, chest pain, abdominal pain, and bloating. These symptoms in the 
absence of typical GERD symptoms point to diseases other than GERD. Careful 
investigation of alternative causes of atypical symptoms is necessary. Sophisticated testing, 
including impedance/pH monitoring, must be performed if GERD is believed to be the 
cause of atypical symptoms and surgery is being considered  (Bajbouj et al 2007; Fornari et al 
2007). Comparing international literature with our case studies we can confirm  that number 
of patients with atypical symptoms referring to our Referral Center for the Surgical 
Treatment of Gastroesophageal Reflux Diseases is growing. In fact 644 patients (30.7%), who 
underwent to endoscopic exams, showed typical and atypical symptoms (heartburn, 
pyrosis, regurgitation, asthma, laryngospasm, pulmonary fibrosis), and 96 patients (4.6%) 
had only atypical symptoms. 
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Reflux esophagitis is defined as reflux causing inflammation or ulceration of the esophagus. 
Attempts have been made to classify the extent of damage, of which the Los Angeles 
classification is now the most commonly used: 
Grade  Extent of esophageal inflammation 
A  Mucosal breaks<5mm not extending between folds 
B  Mucosal breaks>5mm not extending between folds 
C  Mucosal breaks extending between folds 
D  Mucosal breaks  extending between > 2 folds 
  involving  > 75%  of  the  circumference 
4. Diagnosis 
The signs and symptoms are insufficient to establish a conclusive diagnosis of GERD, 
regardless of their frequency and intensity, resulting in a diagnostic certainty of around 
40%. Endoscopy is not usually performed in young adults patients with typical history of 
GERD since it does not alter the clinical evolution when compared to the empiric treatment. 
In patients with non-erosive GERD, the use of the symptom score (moderate or severe) 
allows a diagnostic certainty of up to 40% of the cases. In these cases, the upper digestive 
endoscopy (UDE) does not alter the clinical evolution, when compared to the empiric 
treatment. It is interesting to remember that, in cases of erosive GERD with typical 
symptoms, however, the UDE improves the diagnostic accuracy and also establishes a 
differential diagnosis with other diseases, such as cancer. The 24-hour pH-metry is the most 
important resource for a definite diagnosis of acid reflux, which constitutes most of reflux 
episodes, establishing or ruling out the diagnosis with a 90% and 95% certainty, 
respectively. Actually the acid component of the gastric refluxate is responsible for most of 
the symptoms and pathology associated with GERD, however, other components, such as 
bile, may also contribute (known as nonacidreflux). Quantification of reflux can be achieved 
either by measuring acid exposure to the distal esophagus (pH studies) or movement of 
liquid in the distal esophagus (impedance studies). Combined impedance and pH 
measurement characterizes all acid and non-acid reflux episodes. 
Nearly 70% of patients with heartburn do not have evidence of erosive changes on 
endoscopy. Of these, a proportion have increased acid reflux on 24-hour pH monitoring and 
are classified as having non-erosive reflux disease (NERD) (Jones et al 1995). 
In patients with atypical manifestations, the conventional esophageal pH-metry contributes 
little to the diagnosis of GERD. The current available evidence does not support the routine 
use of proximal pH monitoring. In patients with atypical manifestations, the impedance-pH-
metry substantially contributes to the diagnosis of GERD. In patients undergoing prolonged 
treatment with PPI, the histological esophageal alterations can remain practically unaltered, 
regardless of the occurrence or not of symptoms and signs. On the other hand, the 
histological alterations accompany the degree of severity of the esophagitis. Therefore, the 
evaluation of the histological signs increases the diagnostic probability of GERD. The 
observation of the dimensions of the distal esophagus intercellular space increases the 
probability of diagnostic certainty and also allows the analysis of the therapeutic response. 
Esophageal biopsies in patients with suspected GERD for the analysis of basal cell 
proliferation allow, in absence of the latter, ruling out the diagnosis or active disease. The 
isolated presence of the basal layer proliferation, however, has little diagnostic value. 
Although the basal cell thickness allows the analysis of the therapeutic response, it is not 
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correlated with the clinical response. The presence of reflux symptoms in asthmatic patients 
results in a small increase in the probability of diagnostic certainty. In asthmatic patients 
with reflux symptoms, the normal pH-metry can predict the absence of therapeutic response 
with PPI. A significant number of patients with asthma (57%) also present gastroesophageal 
reflux.GERD may also produce esophageal injury. Esophagogastroduodenoscopy (EGD) 
with biopsy has replaced the upright air-contrast phase of the barium esophagram for 
mucosa evaluation. EGD and biopsy both diagnose and assess esophageal injury by visual 
and histopathologic mucosal examination. Visual assessment of esophageal injury is graded 
using the Los Angeles classification.  Histopathologic findings, although nonspecific, are 
confirmatory in the clinical setting of GERD. The finding of specialized columnar epithelium 
(Barrett esophagus) in the tubular esophagus is secondary to GERD. In the absence of 
dysplasia, surveillance esophagoscopy and biopsy are required in patients who have Barrett 
esophagus, regardless of therapy (medical or surgical). 
If dysphagia is the predominant symptom and the diagnosis is in question,  the examination 
should start as a timed barium esophagram. 
Esophageal manometry excludes unsuspected motility disorders or motility disorders 
masquerading as GERD, confirms adequate esophageal peristalsis for GERD surgery, and 
quantifies preoperative resting pressure and relaxation of the lower esophageal sphincter for 
later comparison. It must be considered in all surgical patients when clinically or ph-
metrically a motility disorder is suspected. 
5. Management 
The aim of GERD treatment is to effectively control symptoms and prevent GERD-
associated complications. As with many conditions, adopting a stepped approach to 
treatment helps tailor disease severity to treatment regimen. 
5.1 Lifestyle changes 
Simple manoeuvres may have a marked effect on symptoms. These are outlined below: 
 dietary changes. Some substances influence oesophageal physiology favouring 
increased acid   reflux. These include fat, caffeine and alcohol 
 avoiding late meals. Acid reflux episodes are prolonged when asleep as a result of both 
gravity, and also reduced peristalsis and acid clearance. Nocturnal reflux can therefore 
be minimised by consuming small meals long before sleep 
 although the association of obesity and GERD is unclear, there does appear to be an 
association with esophageal adenocarcinoma and many other well-known diseases.11 
On this basis weight loss is suggested as part of GERD management. 
5.2 Antacids/alginate combinations 
Antacids consist of calcium carbonate, magnesium and aluminum salts in various 
compounds or combinations. The effect of antacids is due to partial neutralization of gastric 
hydrochloric acid and inhibition of the proteolytic enzyme, pepsin. Alginate mechanism of 
action is due to the formation of a gel in the presence of gastric acid. Alginate-based 
reforming formulations usually contain sodium or potassium bicarbonate; in the presence of 
gastric acid, the bicarbonate is converted to carbon dioxide, which becomes entrapped 
within the gel precipitate, converting it into a foam which floats on the surface of the gastric 
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contents, much like a raft on water. Both in vitro and in vivo studies have demonstrated that 
alginate-based rafts can entrap carbon dioxide, as well as antacid components contained in 
some formulations, thus providing a relatively pH neutral barrier. Antacids and alginates 
have been shown to improve reflux symptoms, however, they do not heal oesophagitis 
(Stanciu et 1974). They are indicated for very mild symptoms, where step-up treatment is 
not necessary. There is no role for antacids/alginates in the maintenance of GERD. 
Despite the development of potent medications for the treatment of GERD, antacids remain 
a mainstay of treatment. Antacids neutralize the acid in the stomach so that there is no acid 
to reflux. The problem with antacids is that their action is brief. They are emptied from the 
empty stomach quickly, in less than an hour, and the acid then re-accumulates. The best 
way to take antacids, therefore, is approximately one hour after meals or just before the 
symptoms of reflux begin after a meal. Since the food from meals slows the emptying from 
the stomach, an antacid taken after a meal stays in the stomach longer and is effective 
longer. For the same reason, a second dose of antacids approximately two hours after a meal 
takes advantage of the continuing post-meal slower emptying of the stomach and 
replenishes the acid-neutralizing capacity within the stomach. 
Antacids may be aluminum, magnesium, or calcium based. Calcium-based antacids (usually 
calcium carbonate), unlike other antacids, stimulate the release of gastrin from the stomach 
and duodenum. Gastrin is the hormone that is primarily responsible for the stimulation of 
acid secretion by the stomach. Therefore, the secretion of acid rebounds after the direct acid-
neutralizing effect of the calcium carbonate is exhausted. The rebound is due to the release 
of gastrin, which results in an overproduction of acid. Theoretically at least, this increased 
acid is not good for GERD. 
Acid rebound, however, has not been shown to be clinically important. That is, treatment 
with calcium carbonate has not been shown to be less effective or safe than treatment with 
antacids not containing calcium carbonate. Nevertheless, the phenomenon of acid rebound 
is theoretically harmful. In practice, therefore, calcium-containing antacids such as Tums 
and Rolaids are not recommended. The occasional use of these calcium carbonate-
containing antacids, however, is not believed to be harmful. The advantages of calcium 
carbonate-containing antacids are their low cost , the calcium they add to the diet, and their 
convenience as compared to liquids. 
Aluminum-containing antacids have a tendency to cause constipation, while magnesium-
containing antacids tend to cause diarrhea. If diarrhea or constipation becomes a problem, it 
may be necessary to switch antacids or alternately use antacids containing aluminum and 
magnesium. 
5.3 Histamine antagonists 
Although antacids can neutralize acid, they do so for only a short period of time. For 
substantial neutralization of acid throughout the day, antacids would need to be given 
frequently, at least every hour. The first medication developed for more effective and 
convenient treatment of acid-related diseases, including GERD, was a histamine 
antagonist, specifically cimetidine. H2 antagonists are very good for relieving the 
symptoms of GERD, particularly heartburn. However, they are not very good for healing 
the inflammation (esophagitis) that may accompany GERD. In fact, they are used 
primarily for the treatment of heartburn in GERD that is not associated with inflammation 
or complications, such as erosions or ulcers, strictures, or Barrett's esophagus. Four 
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different H2 antagonists are available by prescription, including cimetidine, ranitidine, 
nizatidine, and famotidine. All four are also available over-the-counter (OTC), without the 
need for a prescription. However, the OTC dosages are lower than those available by 
prescription. Histamine is an important chemical because it stimulates acid production by 
the stomach. Released within the wall of the stomach, histamine attaches to receptors 
(binders) on the stomach's acid-producing cells and stimulates the cells to produce acid. 
Histamine antagonists work by blocking the receptor for histamine and thereby 
preventing histamine from stimulating the acid-producing cells. (Histamine antagonists 
are referred to as H2 antagonists because the specific receptor they block is the histamine 
type 2 receptor.) Because histamine is particularly important for the stimulation of acid 
after meals, H2 antagonists are best taken 30 minutes before meals. The reason for this 
timing is so that the H2 antagonists will be at peak levels in the body after the meal when 
the stomach is actively producing acid. H2 antagonists also can be taken at bedtime to 
suppress nighttime production of acid. 
5.4 Proton pump inhibitors 
The second type of drug developed specifically for acid-related diseases, such as GERD, was 
a proton pump inhibitor (PPI), specifically, omeprazole. A PPI blocks the secretion of acid 
into the stomach by the acid-secreting cells. Proton pump inhibitors (PPIs) bind to enzymes 
in the stomach membrane that produce hydrochloric acid. PPIs reduce levels of stomach 
acid, and are commonly used to reduce acid reflux symptoms, heal ulcers, and treat 
gastroesophageal reflux disease (GERD).The advantage of a PPI over an H2 antagonist is 
that the PPI shuts off acid production more completely and for a longer period of time. Not 
only is the PPI good for treating the symptom of heartburn, but it also is good for protecting 
the esophagus from acid so that esophageal inflammation can heal. PPIs are used when H2 
antagonists do not relieve symptoms adequately or when complications of GERD such as 
erosions or ulcers, strictures, or Barrett's esophagus exist. Five different PPIs are approved 
for the treatment of GERD, including omeprazole, lansoprazole, rabeprazole, pantoprazole, 
and esomeprazole. A fifth PPI product consists of a combination of omeprazole and sodium 
bicarbonate. PPIs are best taken an hour before meals. The reason for this timing is that the 
PPIs work best when the stomach is most actively producing acid, which occurs after meals. 
If the PPI is taken before the meal, it is at peak levels in the body after the meal when the 
acid is being made. Esomeprazole 20/40 mg/day, lansoprazole 30 mg/day, omeprazole 
20/40 mg/day, pantoprazole 40 mg/day and rabeprazole 20 mg/day are equivalent in the 
treatment of patients with erosive and non-erosive GERD. The report of the occurrence of 
neoplasia with the chronic use of PPI is not supported by evidence. The gastric mucosa, 
however, is altered in these conditions (chronic gastritis, atrophy and polyps of fundic 
glands). The prevalence of gastric atrophy signs increases along the years, mainly when H. 
pylori is present. 
At the primary care level, PPI or a combination of alginate-antacid and acid suppressive 
therapy can be administered at the discretion of the physician, as combination therapy, 
which may potentially be more beneficial than acid suppressive therapy alone. Similarly, 
patients who fail full-dose PPIs, plus/minus adjuvant therapies, may benefit from step-up 
therapy to twice daily PPIs even if there is no difference in randomized studies regarding 
the clinical response to the treatment with PPI taken as two daily doses, when compared to a 
single daily dose. 
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When the PPI were used in full dose (esomeprazole: 20 mg/day and 40 mg/day; 
lansoprazole: 15 mg/day and 30 mg/day; omeprazole: 40 mg/day; pantoprazole 20 
mg/day and 40 mg/day; rabeprazole: 10 mg/day and 20 mg/day), no statistical difference 
was observed between 4 and 8 weeks of treatment. Nevertheless, in cases of therapeutic 
failure, the time of treatment can be extended from 4 to 8 weeks, as although no significant 
difference was observed between the two periods, the number of satisfactory responses is 
higher after 8 than after 4 weeks. 
5.5 Pro-motility drugs 
Pro-motility drugs work by stimulating the muscles of the gastrointestinal tract, including 
the esophagus, stomach, small intestine, and/or colon. One pro-motility drug, 
metoclopramide, is approved for GERD. Pro-motility drugs increase the pressure in the 
lower esophageal sphincter and strengthen the contractions (peristalsis) of the esophagus. 
Both effects would be expected to reduce reflux of acid. However, these effects on the 
sphincter and esophagus are small. Therefore, it is believed that the primary effect of 
metoclopramide may be to speed up emptying of the stomach, which also would be 
expected to reduce reflux. Pro-motility drugs are most effective when taken 30 minutes 
before meals and again at bedtime. They are not very effective for treating either the 
symptoms or complications of GERD. Therefore, the pro-motility agents are reserved either 
for patients who do not respond to other treatments or are added to enhance other 
treatments for GERD. 
5.6 Foam barriers 
Foam barriers provide a unique form of treatment for GERD. Foam barriers are tablets that 
are composed of an antacid and a foaming agent. As the tablet disintegrates and reaches the 
stomach, it turns into foam that floats on the top of the liquid contents of the stomach. The 
foam forms a physical barrier to the reflux of liquid. At the same time, the antacid bound to 
the foam neutralizes acid that comes in contact with the foam. The tablets are best taken 
after meals (when the stomach is distended) and when lying down, both times when reflux 
is more likely to occur. Foam barriers are not often used as the first or only treatment for 
GERD. Rather, they are added to other drugs for GERD when the other drugs are not 
adequately effective in relieving symptoms. There is only one foam barrier, which is a 
combination of aluminum hydroxide gel, magnesium trisilicate, and alginate. 
6. Surgery 
When the diagnosis of reflux is objectively confirmed, surgical therapy should be considered 
in individuals who  (Rice et al 2008): 
1. have failed medical management (inadequate symptom control, severe regurgitation 
not controlled with acidsuppression, or medication side effects) 
OR 
2. opt for surgery despite successful medical management (due to quality of life 
considerations, lifelong need for medication intake, expense of medications, etc.) 
OR 
3. have complications of GERD (e.g., Barrett's esophagus, peptic stricture)  (Spechler et 
1996; Lagergren et al 1999) 
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4. have extra-esophageal manifestations (asthma, hoarseness, cough, chest pain, 
aspiration)  (Rakita et al 2006; Oelshlager et al 2002). 
The coexistence of Barrett’s esophagus with gastroesophageal reflux symptoms is 
considered by many a clear indication for antireflux surgery (Oelshlager et al 2002). 
Surgical intervention for asymptomatic Barrett’s esophagus is more controversial, 
however. While the metaplastic changes of Barrett’s have been reported to regress to a 
greater degree in the post-surgical population compared with medically treated patients, 
to date there is no demonstrable improvement in esophageal adenocarcinoma rates  (Rossi 
et al 2006; Chang et al 2007).  
Today there is increased tendency worldwide to utilize surgery in the earlier stages of the 
disease (Spechler et al 2001). This change in clinical practice is mainly due to advancements 
in surgical technique, the increased patient satisfaction by laparoscopy, and the increased 
awareness of the impairment in quality of life of patients who are not efficiently treated. 
Moreover, the increasing enthusiasm of patients and surgeons for minimally invasive 
surgery has led to the wider application of laparoscopy in the management of GERD in 
many institutes worldwide. 
The large success of laparoscopic surgery as an effective treatment of gastroesophageal 
reflux disease, has established minimal invasive surgery as the gold standard in the surgical 
treatment of this condition.    
The guidelines from American Society for Gastrointestinal and Endoscopic Surgeons 
(SAGES) claim that surgery in GERD is curative in 85-93% of cases and suggest that the 
procedure may be appropriate in patients who have failed medical management, decide for 
surgery despite successful medical management, have complication of GERD, have medical 
complications attributable to a large hiatal hernia, or have “atypical” symptoms and reflux 
documented on 24h pH monitoring  (SAGES Guidelines 2010). 
Antireflux surgery has been shown to be very effective in relieving symptoms in 88-95% of 
patients, with excellent patients satisfaction, both in short and long term studies  (Laffularde 
et al 2001; McKenzie et al 1996).  
There are several trials favoring the clinical outcome of laparoscopic antireflux surgery 
compared to long-term PPI therapy. A large randomized clinical trial from the UK has 
shown significantly better physiological control of reflux in patients having undergone 
laparoscopic Nissen fundoplication than patients under maintenance PPI therapy  
(Laffularde et al 2001).  
A randomized trial with 5-year follow-up, demonstrated that antireflux surgery is more 
effective than proton pomp inhibitor (PPI) drugs in controlling GERD symptoms  
(Laffularde et al 2001; Lundell et al 2001). 
At 7-years follow-up Lundell et all reported the results of a randomized controlled trial of 
patients with esophagitis treated with omeprazole or surgery. The two treatments were 
similar regarding the incidence of recurrent esophagitis (10.3% omeprazole versus 11.8% 
antireflux surgery). In addition the two therapies appeared to be equivalent in healing 
esophageal mucosa  (Lundell et al 2007).  
Another randomized trial, with 10 year follow-up, evaluating the effectiveness of medical 
therapy (omeprazole) versus antireflux surgery found that patients who underwent 
surgery had improved symptoms’ relief when compared to the medically treated group  
(Spechler et al 2001).  
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After 1991 when Dallemagne et al  (Dallemagne et al 1991)performed the first laparoscopic 
Nissen Fundoplication, this technique was preferred to open procedures to result in lower 
morbidity and mortality, shorter hospital stay, faster recovery and less postoperative pain.  
In a review by Catarci et al, laparoscopic fundoplication was as effective as its open 
counterpart  with reduced morbidity, shorter hospital stay, and recovery but without any 
significant difference in early functional results and outcome  (Catarci et al 2004).  
Salminen et al in a recent randomized controlled trial, with 11-year follow-up, compared 
laparoscopic approach and conventional Nissen Fundoplication and concluded that the 
open and laparoscopic approaches for the Nissen fundoplication have similar long-term 
subjective symptomatic outcome despite the significantly higher evidence of incisional 
hernia and defective fundic wraps at endoscopy in the open group  (Salminen et al 2007). 
In a recent review Peters and colleagues compared 503 laparoscopic anti-reflux surgery and 
533 open anti-reflux surgery. In this meta-analysis the authors conclude that laparoscopic 
anti-reflux surgery enables a faster convalescence and return to productive activity, with a 
reduced risk of complications and a similar treatment outcome compared with that of the 
open approach  (Peters et al 2009). 
The surgical management of GERD has been difficult to study scientifically because of the 
significant variation in the surgical techniques used.  
The LOTUS trial  (Attwood et al 2008)was designed to identify a methodology  for 
standardization of the surgical technique and to measure the effectiveness of this 
standardization. This study has shown that surgeons are able to standardize their work for 
the purpose of measuring the outcome of an operative procedure within the context of a 
randomized trial.  
Several series have shown the early outcomes of laparoscopic Nissen fundoplication to be 
excellent, with minimal morbidity and mortality, marked reduction in distal esophageal 
acid exposure, and symptom control for the overwhelming majority of patients. There have 
been multiple series with 5-year outcomes following Laparoscopic Nissen Fundoplication 
(Table 1). Heartburn was controlled in approximately 90% of patients, the revision rate was 
between 1 and 17%, and 86%-92% of patients that were off antireflux medications.  
In the German experience, in 164 hospitals performing laparoscopic antireflux surgery and 
2053 operation were reported in 1999. In 65% of the cases the surgical procedures were total 
fundoplication, in 31% partial fundoplication and in 4% other techniques. In total 
fundoplication there were 5 different techniques, in partial plication 5 and in the other 
group 3  (Huttl et al 2005). 
Actually in laparoscopic antireflux surgery there are two debated questions today: if partial 
or total fundusplication must be performed and if this last is preferred division of short 
gastric vessels  must be routinely performed or not.  
6.1 Partial versus total fundoplcation 
The total fundoplication involves a 360-degree wrap of the gastric fundus around the 
esophagus and is the most commonly performed anti-reflux operation. Total wrap (Nissen) 
supports and acknowledge the fact that the wrap needs to be “floppy” to minimize 
postoperative dysphagia  (DeMeester et al 1986). It should also be noted that a floppy Nissen 
fundoplication is safe and effective in patients suffering from a defective esophageal 
peristalsis. Finally, proponents of the Nissen note a decreased  effectiveness of a partial 
Fundoplication in controlling reflux symptoms. 
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Series FU (years) N (%FU) %Hb Relief (0-1) Revision (%)
Off PPI+H2-A 
(%) 
Morgenthal et al. 2007 
(Emory, GA, USA) 
11,0 166 (59) 89 10,8 70 
Dallemagne et al. 2006 
(Belgium) 
10,3 45 (66) 96 1,4 92* 
Kelly et al. 2007 
(Australia) 
10 226 (90) 84 17 79 
Zaninotto et al. 2007 
(Italy) 
8,1 138 (95) - 9,4 79 
Bammer et al. 2001 (mayo, 
FL, USA) 
6,4 171 (59) 94 1,0 86* 
Laffularde et al. 2001 
(Australia) 
6 166 (93) 87 14,2 89 
Oelschlager et al 2008 
(Seattle, WA, USA) 
5,8 288 (65) - 3  
Anvari, Allen 2003 
(Ontario, Canada) 
5 181 (48) - 3,6 88 
Booth et al. 2002 
(England) 
4 140 (78) 90 6,3 86 
FU= follow-up; HB= heartburn; 0-1= none-mild; *Does not include patients on H2-A 
Table 1. Laparoscopic 360° Fundoplication Series 
Two partial fundoplications are commonly performed, the Dor and Toupet fundoplication 
(anterior and posterior wrap). Of these two partial wraps, the Toupet is the most commonly 
performed partial Fundoplication  (Roberts et al 2006). 
The Nissen procedure finds excellent symptomatic control but is reported to also have a 
high postoperative dysphagia rate and specific side effects such as inability to belch and 
vomit, and gas bloat syndrome  (Sgromo et al 2008; Watson et al 2001). 
The Toupet procedure is thought to produce less postoperative side effects than the Nissen 
procedure but studies have indicated that the recurrence rate of reflux symptoms may be 
higher after this procedure  (Yobe et al 1997; Fernando et al 2002). 
Horvath et al defines in a study the preoperative risk factors that predispose patients to 
failure. Data from 48 patients with objective follow-up performed as a part of a prospective 
long-term outcome project: 24-h pH-monitoring, manometry, esophagogastroduodenoscopy 
at 6 months, 3 years and 6 years, was analyzed (Horvath et al 1999). Patients in whom 
testing was completed were divided into two groups based on their results: those whose 
procedures failed (n=22) and those who had a successful outcome after a Toupet 
fundoplication  (n=26). Surgical failure was defined as an abnormal postoperative De 
Meester score, with or without symptomatic recurrence. The authors shows that age, sex, 
primary and secondary presenting symptoms, presence of hiatal hernia, and esophageal 
dysmotility were not predictive of failure following a Toupet procedure and the numbers of 
years of GERD symptoms before surgery also did not predict failure after Toupet 
fundoplication. Horvath and colleagues concluded that the laparoscopic Toupet 
fundoplication appears to provide a weaker antireflux barrier than the Nissen procedure 
and is probably an insufficient procedure for patients with severe GERD. It may also 
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predispose patients to postoperative mediastinal warp hernation. Independent preoperative 
predictors of failure after Toupet were: 
- LES pressure <5mmHg an preoperative manometry, 
- Distal esophageal aperistaltic segment, 
- Biopsy proved Barrett’s metaplasia, 
- Presence of stricture, 
- Grade III or IV esophagitis an endoscopy, 
- Preoperative De Meester score >50.          
Guerin et al in a recent randomized trial with a 3 years follow-up, compared Nissen versus 
Toupet Fundoplication. Both groups in this study presented comparable preoperative 
findings (Guerin et al 2007). The Toupet procedure presented a higher level of invaliding 
functional symptoms in the immediate postoperative period, and the difference with the 
Nissen Fundoplication group was statistically significant for hyperflautolence, solids 
dysphagia and incapacity to belch. But at 1 and 3 years follow-up there wasn’t any 
statistically significant difference of invalidating symptoms and the satisfaction level 
remained high. The authors concluded that the choice of the technique did not seem to be 
determined by the preoperative investigations, except when it diagnosticated a brachy 
esophagus and they also confirmed that laparoscopic Nissen or Toupet Fundoplication 
provides a high level of patients satisfaction despite invalidating side effects during the first 
postoperative year.   
Strate et al compared laparoscopic Toupet and Nissen Fundoplication in 200 patients with 
esophageal motility disorders within 2 years follow-up (Strate et al 2008). The authors led to 
the following conclusion: 
- Esophageal motility disorder does not effect postoperative clinical outcome and 
requires no tailoring of surgical management; 
- The Toupet procedure is more effective in reflux control; 
- Postoperative dysphagia is significantly higher after Nissen Fundoplication; 
- Toupet Fundoplication reduces the rate of reoperation due to mechanical failure. 
For Strate and colleagues the Toupet Fundoplication seems to be the better operative 
procedure for patients suffering from GERD.  
Another similar randomized clinical trial by Booth and colleagues compared the two 
procedures in 127 patients considering preoperative esophageal manometry after 1 year 
follow-up (Booth et al 2008). In the study there was no significant difference in the 
prevalence or severity of symptoms after surgery between the Nissen group and Toupet 
group except for a greater prevalence of dysphagia and chest pain when eating in the Nissen 
group and there were no postoperative differences in the prevalence or severity of 
symptoms between the effective and ineffective motility groups, other than an increased 
severity score for flatus in the effective motility group 6 months after surgery. At 1 year 
follow-up there were no significant differences in Visick score between Nissen and Toupet 
group. The authors provides no clear conclusions regarding the efficacy and durability of 
Nissen compared with Toupet Fundoplication in controlling the reflux symptoms of 
heartburn and regurgitation, although there are greater postoperative acid exposure time 
and more pH failures in the Toupet group. 
Sgromo et al compared the long-term outcome of Nissen and Toupet fundoplication by 
evaluating symptoms and quality of life at 7 years follow-up (Sgromo et al 2008). The 
authors concluded that long-term satisfaction, general symptoms score and quality of life 
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were equivalent after laparoscopic Nissen or Toupet fundoplication, despite, a significantly 
increased prevalence of persistent heartburn after laparoscopic Toupet fundoplication. 
Kamolz et al used the Gastrointestinal Quality of Life Index (GIQLI) for evaluating Nissen 
laparoscopic fundoplication versus Toupet procedure (Kamolz et al 2002). At 3 years and 
5 years follow-up, the analysis of quality of life data showed that the GIQLI score 
remained stable in comparison with the 1 year follow-up data. Patients satisfaction with 
surgery was rated as “excellent” or “good” in 97.7% of patients. There were no significant 
differences between the 2 groups. The authors concluded that quality of life scores for 
both surgical groups were almost equal and postoperative outcome were comparable to 
values in healthy controls. 
In a similar retrospective study, Zugel et al compared the results of 122 Toupet and 40 
Nissen laparoscopic fundoplication in terms of patients satisfaction at 19 months follow-up. 
Both groups offered effective therapy for reflux, with more than 90% patient satisfaction 
(Zugel et al 2002). The authors concluded that both surgical techniques were effective in the 
treatment of GERD. 
Laws et al used a randomized prospective study to compare the Nissen fundoplication 
versus the Toupet fundoplication for GERD (Laws et al 1997). At 27.2 months follow-up, 
postoperative symptomatology was judged using a modified Visick scale using the 
following grades in 38 patients: 
- I no symptoms, 
- II minimal symptoms, no lifestyle changes, no need to see a doctor, 
- III significant symptoms requiring lifestyle changes of doctor’s help, 
- IV debilitating symptoms or reoperation. 
There were no grade IV’s. At follow-up, Visick score after the Nissen wrap were I-13, II-8, 
III-2 and after the Toupet procedure were I-12 and II-3. The authors concluded that a partial 
or complete wrap after division of the short gastric vessels offers effective therapy for reflux 
esophagitis with >90% patients satisfaction. 
Farrell and colleagues compared the effectiveness and durability of Toupet (79 pts) and 
Nissen (59 pts) procedures as a function of preoperative esophageal motility (Farrell et al 
2000). Patients scored heartburn, regurgitation and dysphagia preoperatively, and at 6 
weeks and 1 years, using 0 to 3 scale. At 6 weeks after operation, heartburn and 
regurgitation were similarly improved in both groups, but dysphagia was more prevalent 
among Nissen patients. After 1 year, heartburn and regurgitation were re-emerging in 
Toupet patients, and dysphagia was again similar between groups. Patients with impaired 
motility who have Nissen fundoplication are no more likely to suffer persistent dysphagia 
than their counterparts who have Toupet fundoplication. But, patients with normal motility 
are more likely to develop symptoms recurrence after Toupet fundoplication than Nissen 
procedure, with no distinction in dysphagia rates. The authors concluded that Toupet 
patients suffer more heartburn recurrence than Nissen patients, with similar dysphagia. 
Fernando et al compared Toupet procedure versus Nissen fundoplication (Fernando et al 
2002). Extended outcome and quality of life measurement (SF36 and HRQOL) were 
available for 142 patients at a mean follow-up of 19.7 months. Since there was a potential 
bias with a greater proportion of esophageal dysmotility with Toupet patients, further 
analysis was performed by dividing patients into four groups: group 1, Nissen patients with 
decreased motility; group 2, Toupet patients with decreased motility; group 3, Nissen 
patients with normal motility; and group 4, Toupet patients with normal motility. 
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Comparison were made as follows: group 1 versus group 2, group 3 versus group 4, and 
group decreased motility versus group normal motility. There were no significant 
differences between Nissen and Toupet groups except for a higher incidence of dysphagia in 
the Toupet group. Resumption of proton pump inhibitors was required in 20% Nissen 
patients compared to 38% Toupet patients (p<0.05). Only 7% in the Nissen group were 
dissatisfied with their surgery compared to 21% patients in the Toupet group (p<0.05). The 
SF36 scores were similar in all quality of life domains except for the domain of physical 
function, where better scores were seen in the Nissen group compared to the Toupet group 
(p<0.05). Comparison of group 1 versus group 2 revealed no significant difference in SF36 
and HRQOL scores, symptoms, and medication use. Comparison of group 3 versus 4 
demonstrated slightly worse HRQOL scores in the Toupet group and poorer scores (p<0.05) 
in the SF36 domains of vitality and mental health for the Toupet patients. The Toupet 
patients with normal motility also complained of more dysphagia and waterbrash (p<0.05). 
Comparison was also made between patients with impaired motility and those with normal 
motility. There were no differences in SF36 scores, HRQOL score, symptoms and medication 
use. This analysis supports the hypothesis that the differences seen were related to 
differences in esophageal motility. Surprisingly, they found more dysphagia in the Toupet 
group. These differences was not seen when they were analyzing the results of patients in 
the impaired motility groups but was present in patients with normal motility. The reason 
for this is unclear but may be related to a greater degree of recurrent esophagitis because of 
reflux in Toupet patients.     
Dallemagne and colleagues compared laparoscopic Nissen fundoplication versus Toupet 
procedure at 5 years and 10 years follow-up (Dallemagne et al 2006). At 5 years follow-up, 
58 Nissen patients and 28 Toupet patients completed the study, and at 10 years 49 Nissen 
and 20 Toupet patients completed the follow-up. At 5 years the heartburn was relieved in 
98% of the Nissen group and 86% of the Toupet group. There was no significant difference 
between the two groups. Ten years after surgery the heartburn still was controlled in 96% of 
Nissen patients and 90% of Toupet group. Also in this case there was no significant 
difference between the two groups. Kaplan-Meier estimates of recurrence-free proportion 
were evaluated and control of reflux was still obtained in 93.3% of the Nissen groups and 
81.8 % of Toupet patients at 10 years (p=0.17). There was no significant difference in the 
incidence of side effects between partial and total fundoplication. The incidence of 
postoperative dysphagia in patients with preoperative impaired esophageal motility was 
not different after partial or total fundoplication. Dallemagne and colleagues concluded that 
Nissen patients have better results than Toupet patients, although the differences was not 
statistically significant and they observed more recurrences after partial fundoplication than 
after Nissen fundoplication.      
Fein et al compared partial fundoplication versus total fundoplication at 10 years follow-up. 
88 patients received a Nissen procedure and 10 a Toupet fundoplication (Fein et al 2008). 
Follow-up of the patients included disease-related questionnaire and GastroIntestinal 
Quality of Life Index (GIQLI). Positive pH score were 21% in Nissen group and 56% in 
Toupet patients. The heartburn was present in 29.7% of Nissen groups and 12.5% of Toupet 
patients, regurgitation in 15.1% of the Nissen group and 10% of the Toupet group, 
dysphagia in 30.6% of the Nissen group and 28.6% of the Toupet group. Patients who had 
undergone Toupet fundoplication (43%) took proton pump inhibitors significantly more 
often than patients who underwent Nissen fundoplication (14%). None of the differences 
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regarding the various procedures were significant about the GIQLI. In the observational 
scores, Nissen fundoplication appeared to control reflux better than partial fundoplication. 
In conclusion, despite the difficulties in comparing the result of single experiences of partial 
and total placation almost all combined experiences reported a good clinical and 
instrumental result for Toupet and Nissen procedures with light preference of Nissen for a 
better reflux control with similar others side effects.   
6.2 Division versus non division of the short gastric vessels 
The total fundoplication wrap achieves very effective control of reflux, although it can be 
followed by some troublesome side effects, such as dysphagia, gas bloat and inability to 
belch. To minimize the risk of developing these side effects, Nissen’s procedure has been 
modified in a variety of ways concerning the length of the placation (short: 2 cm, long: 3-4 
cm), its contention’s degree (tight or floppy), the fixation of posterior wrap to the diaphragm 
or the esophagus, the routine iatal repair and the routine division of the first two or three 
short gastric vessels (true, Nissen) or it’s preservation (Rossetti variation). There is a general 
agreement in literature to prefer a short floppy placation with no routine iatal repair and no 
wrao fixation. A still debated question is the significance of short gastric vessels division 
(deMeester et al 1986). It has been claimed that this step is followed by a lower risk of 
dysphagia, gas bloat and other side effects (deMeester et al 1986; Donehaue et al 1985)     
However, some surgeons claim that an equally good outcome can be achieved without 
dividing these vessels   (Rossetti et al 1977; Watson et al 1997; Watson et al 1995; Anvari et al 
1996) and this evidence is confirmed by randomized controlled trial. 
Chryos et al in a prospective randomized trial compared Nissen (with division gastric 
vessels) to Nissen-Rossetti (without division gastric vessels) technique after 12 months 
follow-up (Chryos et al 2001). The authors concluded that division of short gastric vessels 
while performing laparoscopic Nissen fundoplication does not improve clinical outcome 
and laboratory finding in patients with GERD, and, at the same time, is associated with 
prolongation of the operating time and increased incidence of postoperative gas bloat 
syndrome. 
In a recent multicentric trial of 1340 patients, Pessaux et al, concluded that the division of 
short gastric vessels did not improve clinical outcome after 2 or 5 years follow-up and 
increased the incidence of gas discomfort (Pessaux et al 2005). 
In a recent randomized controlled trial Yang, Watson and colleagues reported the clinical 
outcome at 10 years follow-up (Yang et al 2008). The surgeons of this study have just 
reported the 6 months and 5 years outcome from this trial in previous publications  (O’Boyle 
et al 2002; Watson et al 1997).   
The authors confirm what many other papers claim: the division of the short gastric vessels 
does not influence the clinical outcome   (Luostarinen et al 1999; Blomqvist et al 2000). 
At 10 years follow-up, the authors concluded that there were no significant differences 
between the 88 patients that completed the study for either incidence or severity of 
dysphagia, heartburn, or overall satisfaction. These outcomes were identical to the outcomes 
from the earlier follow-up. 
In a study of 138 patients, Sato et al analyzed the effect of short gastric vessels division on 
postoperative dysphagia (Sato et al 2002). They reported that laparoscopic Nissen 
fundoplication with or without division of short gastric vessels achieved a similar outcome. 
Their research suggested that patient selection and accurate construction of the 
fundoplication were the most important factors in minimizing postoperative dysphagia. 
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Mardani, Lundell and colleagues designed a randomized controlled trial to determine the 
long-term results of total Nissen Fundoplication with or without division of short gastric 
vessels in a 10 years follow-up  (Mardani et al 2009). They reported that mechanical side-
effects remain a problem following construction of a total wrap, and are perhaps of even 
greater concern when the operation is performed laparoscopically. There is a widely held 
view among surgeons that a wrap should be short end tension free   (deMeester et al 1986; 
Rossetti et al 1977). However, the optimal length of total wrap to minimize subsequent 
obstructive complaints remains to be clarified in Mardani and colleagues randomized trial, 
in fact it may sometimes be necessary to divide some of the short gastric vessels in order to 
construct a tension free wrap, but this cannot be recommended in routine surgical practice 
(Mardani et al 2009). In a precedent report the same authors have reported subtle 
manometric differences between the two study groups, offering a physiologic background 
to a potential difference in functional outcome  (Engstrom et al 2004), but it appears that 
these differences in lower esophageal sphincter response to gastric distension with air do 
not translate into important and clinically relevant functional correlates. 
At 10 years follow-up, the authors concluded that with total Fundoplication it makes no 
difference whether the fundus is mobilized or not and that both types of repair provide 
long-lasting control of reflux (Mardani et al 2009). 
Leggett et al. compared laparoscopic Nissen Fundoplication and Rossetti’s modification in 239 
patients, follow-up for the Rossetti group (138 patients) extends from 36 to 82 months and that 
for the Nissen group (101 patients) from 17 to 35 months (Leggett et al 2000). All patients 
experienced relief from symptomatic gastroesophageal reflux, whether they received the 
Rossetti modification or the Nissen Fundoplication. In their series, they found no statistically 
significant differences in intraoperative, postoperative, or overall complications between the 
two procedures. Prolonged postoperative dysphagia requiring dilation was significantly 
higher in the Rossetti group than in the Nissen group. But the percentage of patients requiring 
dilatation in both groups was higher in the first 20 than in the last 20 cases, and the authors 
state that with experience, surgeons become better able to judge the tightness of the crural 
closure, the size of posterior window, and the looseness of the wrap.       
Table 2 shows of results of a different series that compared total fundoplication with or 
without division short gastric vessels. 
In another prospectively randomized trial Kosek and colleagues compared the clinical and 
functional results after total fundoplication with or without division of short gastric vessels 
after five years follow-up (Kosek et al 2009). During long-term follow-up median DeMeester 
score decreased without statistically significant differences between the two groups and 
Gastrointestinal Quality of Life and patient satisfaction were similar in both group. The 
authors concluded that in their patient population division of the short gastric vessels 
during Nissen fundoplication that it has no statistically significant influence on clinical or 
functional outcome during a 5-year follow-up period. They therefore do not recommend 
routine division of the short gastric vessels in the course of total fundoplication. The 
intraoperative decision to divide the vasa gastricae breves may be made in some patients to 
obtain a tension-free fundoplication.  
Finally in spite that many authors still routinely employ Nissen technique to perform a 360 
degree short fundoplication there is no evidence support this position according to 
randomized study. 
Rossetti variation (without section of short gastric vessels) can be “short e floppy”   as well 
according the surgeon’s experience and the use of an endoesophageal bougie of 54 – 60 Fr. 
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Reccurence - - 35 (8,7)
40 
(13,1) 
- - - - 
Heartburn 0 1 (4) - - 18 11 1,9 (1,4) 1,4 (0,7) 
Chest pain 1 (3) 0 1 (0,25) 0 - - - - 
Regurgitation 0 0 - - 17 9 - - 
Respiratory 2 (16) 1 (4) 2 (0,5) 2 (0,6) 20 24 - - 
Dysphagia 5 (16) 4 (17) 26 (6,4) 28 (9,2)   2,4 (1,6) 2,0 (1,5) 
Solids 5 4 - - 44 59 - - 
Liquids 0 0 - - 14 14 - - 
Gas-bloating 
Syndrome 
6 (19) 9 (38) 44 (10,9 26 (8,5) 32 41 - - 
Diarrhea - - 3 (0,7) 7 (2,3) - - 2,6 (1,6) 2,4 (1,5) 
Indigestion - - 3 (0,7) 6 (2) - - 3,1 (1,5) 3,4 (1,2) 
Constipation - - 1 (0,25) 0 - - 2,3 (1,2) 2,4 (1,3) 
Abdominal 
pain 
- - 4 (1) 7 (2,3) - - 2,8 (1,4) 2,5 (1,2) 
Hiccup - - 2 (0,5) 2 (0,6) - - - - 
Flatulence - - 8 (2) 12 (4) - - - - 
Nausea - - 0 1 (0,3) 10 21 - - 
Pt= patients; *=Numbers in parentheses represent percentages. **=Values are mean (s.e.m.). In all series 
no significant differences demonstrated between trial groups.  
Table 2. Laparoscopic Total fundoplication: not divided (Nissen-Rossetti procedure) vs 
divided (Nissen procedure) short gastric vessels 
In the few cases in which a “floppy” placation is not feasible than short gastric vessels must 
be divided and there a Nissen procedure performed.    
In conclusion, Laparoscopic fundoplication is an established treatment for symptomatic 
gastro esophageal reflux disease and must be considered now days as the “gold standard” 
surgical procedure, tailoring a only marginal role to open surgery. It effectively controls 
heartburn and regurgitation, but it can be associated with unwanted effects, principally 
postoperative dysphagia, postprandial fullness, inability to belch or vomit and increased 
passage of flatus (tab. 2). 
The choice of a total (360 degree) or a partial (270 degree) placation is difficult and not 
supported with clear evidence both in randomized and non randomized series, even if a 
better control of reflux symptoms in long follow-up studies gave a reason of a much a larger 
experience of 360 degree plication performed by reflux surgeon. 
Total fundoplication is than the most performed operation for surgical treatment of GERD. 
Division of short gastric vessels (Nissen) or their preservation (Rossetti variation) is the last 
debated point. Randomized and non-randomized studies seem to point out in a precise way 
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that a division of short gastric vessels is unnecessary to perform a “short and floppy” 
placation: the two main objectives to achieve is to prevent post operative dysphagia.     
7. Barrett’s esophagus 
Barrett’s esophagus is an acquired abnormality that is characterized grossly by an upward 
displacement of the squamo-columnar junction, with replacement of the typical whitish 
smooth esophageal mucosa by a velvety, reddish mucosa  (Oelschlager et 2003). The 
columnar-lined esophagus was described by Norman Barrett in 1950 (Barrett 1950), reported 
to be associated with gastroesophageal reflux disease in 1953 (Allison et al 1953) and 
convincingly linked with oesophageal adenocarcinoma in 1975 (Naef et al 1975). The 
paradigm is that Barrett’s esophagus arises as a complication of symptomatic 
gastroesophageal reflux disease and predisposes to esophageal adenocarcinoma. 
BE is detected in approximately 6–12% of patients with GERD (Winters et al 1987, Cameron 
et al 1992). At present, BE is the most common cause of esophageal adenocarcinoma, a 
deadly malignancy with a frequency that has been rising strikingly in Western countries and 
a mortality rate that still exceeds 80%  (Parker et 1997). In the USA, the incidence of 
esophageal adenocarcinoma has increased more than sixfold over the past three decades 
(Pohl et al 2005). The absolute risk of patients with BE for developing cancer is 
approximately 0.5% per year  (Hirota et al 1999). 
The metaplastic mucosa was confirmed by biopsy of the tubular esophagus during 
endoscopy. 
Controversy over criteria for diagnosis of BE primarily concerns whether intestinal 
metaplasia (IM) is required for a diagnosis of BE. In the USA, BE has been defined by the 
Parameters Committee of the American College of Gastroenterology as the metaplastic 
replacement of any length of the esophageal epithelium that can be recognized at endoscopy 
and that is confirmed by biopsy to have specialized intestinal metaplasia, defined by the 
presence of goblet cells  (Wang et al 2008). The vast majority of adenocarcinomas of the 
esophagus are accompanied by IM in multiple studies   (Paraf et al 1995; Cameron et al 1995, 
Smith et al 1984). Therefore, it has been believed that esophageal adenocarcinoma arises in 
intestinal type mucosa with goblet cells within a columnar-lined esophagus (CLE). 
CLE can involve any of three types of epithelium: fundic (gastric), cardial (junctional), and 
specialized intestinal metaplasia. 
The British Society of Gastroenterology does not require confirmation of intestinal 
metaplasia in biopsies from the esophagus to establish this diagnosis (Gastroenterology 
TBSO 2005; Playford et al 2006.  
In the concept of these guidelines, the presence of IM is thought to be less important for the 
diagnosis of BE than the presence of a proper esophageal gland, squamous island, and/or 
double muscularis mucosa (Takubo et al 1991; Takubo et al 1995; Long et al 1999). The most 
important rationale behind this view is related to the high rate of sampling errors at index 
endoscopy. Repeated endoscopy and biopsy are often necessary to confidently detect or 
exclude the presence of IM. Based on a recent retrospective study, an estimated eight 
biopsies are necessary for an adequate assessment of the presence of intestinal metaplasia  
(Harrison et al 2007). Furthermore, a previous study from the UK National Barrett’s 
Oesophagus Registry (UKBOR) has not only confirmed this, but has demonstrated a similar 
neoplastic risk in patients with columnar metaplasia with and without demonstrable 
intestinal metaplasia  (Vaezi et al 1996; Lieberman et al 1997; Locke et 2003; Smpliner et al 
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2002; Watson et al 2005; Shepherd et al 2003; Gatenby et al 2008). The relative risk of 
adenocarcinoma development in patients with columnar-lined esophagus has been 
estimated at 5–125 fold higher than of control populations (Van der Veen et al 1989; 
Bartelsman et al 1992; Iftikar et al 1992; Solaymani-Dodaran et 2004; Anderson et al 2003) 
with the overall annual adenocarcinoma risk in columnar-lined esophagus at 0.69% (range 
0–3.6%) per annum (Gatenby et al 2008). 
Like the British Society of Gastroenterology, the Japan Esophageal Society defines BE as a 
CLE with at least one of the following: a proper esophageal gland, squamous island, or 
double muscularis mucosae (Japan esophageal Society 2009). In a recent review of 141 cases, 
Takubo et al. demonstrated that more than 70% of primary esophageal adenocarcinomas 
were adjacent to cardiac and/or fundic rather than intestinal type mucosa with goblet cells  
(Takubo et al 2009). This suggests BE might be better defined as the presence of metaplastic 
columnar-lined esophagus with or without goblet cells, which is in accordance with the 
British and Japanese definition of BE. As there are still few data on the risk of esophageal 
adenocarcinoma in CLE lacking IM. 
Controversy has surrounded the most appropriate means of reflux control in patients with 
CLE. While pharmacological acid suppression is the least invasive and most suitable for 
elderly patients and those with comorbidity, the high incidence of hiatal hernia, lower 
esophageal sphincter failure, peristaltic impairment, and reflux of duodenal juice renders 
proton pump inhibitor (PPI) therapy less effective in columnar-lined esophagus than in less 
severe reflux disease, with up to 40% still demonstrating pathological acid exposure after 
receiving up to 80 mg per day of omeprazole  (Lundell et al 2001; Katzka et al 1994; 
Sampliner et al 1994; Ouatu-Lascar et al 1998; Sharma et al 1997). Several series have 
suggested that fundoplication, by virtue of its ability to correct hiatal hernia, lower 
esophageal sphincter failure, and reflux of duodenal juice, confers some protection against 
adenocarcinoma development (Wassnaar et al 2010).  
In conclusion BE and CLE may be considered as a synonym.  
Progression of BE in this paper is defined as a change in histological findings on biopsy 
from CLE to any form of dysplasia or an increase in grade of dysplasia. Development of 
adenocarcinoma is also considered progression of disease. Regression is defined as change 
from high-grade dysplasia (HGD) to low-grade dysplasia (LGD) or no dysplasia, change 
from LGD to metaplasia or loss of metaplasia, and change from CLE to complete loss of 
metaplasia. Shortening of the segment or development of squamous cell islands, although 
considered by some as regression, usually is not accurately measured and reported, and is 
therefore, not considered regression in our report. Long-segment BE (LSBE) is defined as > 3 
cm, short segment BE (SSBE) is defined as a length 1- 3 cm seen at endoscopy and confirmed 
by biopsy, ultra-short segment Barrett Esophagus < 1cm. 
The goal of treatment of columnar-lined esophagus is to prevent non-neoplastic 
complications and development of dysplasia and adenocarcinoma by control of 
gastroesophageal reflux while maintaining a healed mucosa  (Sampliner et al 2002).  
Patients with columnar-lined esophagus are among those with the most severe 
gastroesophageal reflux disease (Winters et al 1987; Avidan et al 2002; Liebermann et al 
1997; Locke et al 2003, Csendes et al 2002) and adequate control of reflux is difficult  (Katzka 
et al 1994; Ouatu-Lascar et al 1998; Sharma et al 1997). Medical therapy does not prevent 
biliary reflux into the esophagus (Vaezi et 1996; Manifold et al 2000), and only surgical 
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correction of the defective gastroesophageal sphincter can abolish this (Parilla et al 2003; 
Watson et al 1997; Zaninotto et al 2002).  
Three recent studies have investigated the effect of PPI treatment on the risk of progression 
of BE to dysplasia or adenocarcinoma (Cooper et al 2006; Hillman et al 2004; Nguyen et al 
2009). The results of these controlled studies suggest a protective effect of PPIs in limiting 
the progression of BE, but they do not eliminate the risk of developing AC.  
In the study by Hillman et al, patients were stratified according to delay in starting PPI 
therapy after the diagnosis of BE was established (Hillman et al 2004). Patients who delayed 
PPI therapy for ≥ 2 years after being diagnosed with BE had 5.6 times higher risk of 
developing low grade dysplasia than patients who used PPI within the first year after 
diagnosis. Furthermore, patients with BE had up to a 20 times higher risk of developing 
high grade dysplasia or adenocarcinoma when PPI therapy was delayed for 2 years after 
diagnosis of BE. Although this suggests a substantial protective effect, the absolute risk of 
developing high grade dysplasia or adenocarcinoma was low, 3%, at a median follow-up of 
4.7 years. The small rate of progression of BE makes it very difficult to show a difference 
between treatments.  
In another study, Cooper et al considered 188 patients with IM who were treated with a PPI, 
the risk of developing low grade dysplasia within 5 years of the diagnosis of BE was around 
2.5%, and the risk of high grade dysplasia or adenocarcinoma was around 2% while taking 
PPI therapy (Cooper et al 2006).  
However, when following patients for > 5 years, Nguyen et al recently have found a much 
higher risk of developing adenocarcinoma (Nguyen et al 2009). They have studied 344 
patients diagnosed with BE without dysplasia, with a mean follow-up of 7.6 years. They 
found that the chance of developing HGD or adenocarcinoma was 7.4%. Moreover, this risk 
was even higher when not taking PPIs (14.2%).  
The hypothesis that surgery is superior to medical therapy comes from the assumption 
that surgery provides better control of GERD than do PPIs, and this should translate into 
lower progression rates. There have been very few studies comparing medical and 
surgical therapy.  
Gatenby et al published the results of their review of a cohort of 738 patients with BE 
(Gatenby et al 2009). They compared 41 patients with anti-reflux surgery to 551 treated 
medically with PPIs, 42 patients treated with H2 receptor antagonists (H2RAs), 95 
patients treated with H2RA followed by PPI and 9 patients with treatment. After a follow-
up of 5 years after medical therapy and 6 years after surgical therapy, there was however 
a trend toward antireflux surgery being more protective. No patients in the antireflux 
group developed HGD or AC as compared to 4.3% in the all-medical therapies group (P = 
0.13). There were not enough patients in the surgical arm to determine if this was a 
significant difference.  
Parrilla et al have published the only randomized study comparing 43 patient treated with 
medical treatment and 58 with antireflux surgery (Parrilla et al 2003). In that study, 101 
patients with BE were treated between 1982 and 2000. Medical treatment consisted of H2RA 
treatment initially and then omeprazole from 1992 onward. Surgery was performed through 
laparotomy with Nissen fundoplication in 56 patients and a Collis-Nissen procedure in the 
other two because of short esophagus. All patients had annual clinical, endoscopic and 
histological follow-up, and patients who had an operation also had a pH study and 
manometry at 1 year postoperatively and every 5 years thereafter, or if they presented with 
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recurrent GERD symptoms. Mean follow-up was 6 years for the medical therapy group and 
7 years for the surgical group. Progression of BE to any dysplasia was found in eight 
patients (19%) in the medical treatment group and in three in the surgical group (5%). Two 
patients in each group progressed to adenocarcinoma, which was confirmed after 
esophageal resection. Although differences in progression rates between the two groups 
were not significant according to the authors, when a sub-analysis was performed including 
only patients in the surgical arm with normal pH, the progression rate dropped to 2%, 
which was a significantly lower chance of progression of disease than in the medical group.  
The hypothesis that surgery is superior to medical therapy comes from the assumption that 
surgery provides better control of GERD than do PPIs, and this should translate into lower 
progression rates. The control of reflux is essential in preventing progression of disease, is 
backed up by the fact that, in most studies, the patients with progression after surgical 
treatment seem to have recurrent reflux. This observation, that control of reflux is essential 
in preventing progression of disease, is backed up by the  fact that, in most studies, the 
patients with progression after surgical treatment seem to have recurrent reflux  
(Oelschlager et al 2003; O’Riordan et al 2004; Biertho et al 2007; Lagergren et al 2007; 
Csendes et al 2004). 
Hofstetter et al have published the study with the longest follow-up (Hofstetter et al 2001). 
They showed results for a series of 97 patients, with complete endoscopic follow-up in 79, at 
a median of 5 years. No patients developed HGD or adenocarcinoma, but four had 
progression of metaplasia to LGD (5%).  
Bowers et al, have reported a similar series with a mean follow-up of 4.6 years (Bowers et al 
2002). Their 104 patients underwent open or laparoscopic fundoplication. Of these, 64 
patients had endoscopic follow-up with biopsy. None of the patients developed HGD or 
adenocarcinoma. Only one patient had progression to LGD (1.5%).  
Wassenaar and Oelschlager in a recent review are summarized the result of 11 
publications on surgical treatment for BE that included results on prevention of 
progression, as well as regression of metaplasia or dysplasia (Wassenaar et al 2010). A 
total of 551 patients were considered with a median follow up of 3.6 years. The 
progression rate of metaplasia to dysplasia or adenocarcinoma was 3.4% and 0.7% 
respectively and the regression rate was 30.5%. 
Kamolz and colleagues evaluated and compared quality of life data before and after 
laparoscopic antireflux surgery in GERD patients with and without BE (Kamolz et al 2003). 
The authors concluded that non-BE patients undergoing laparoscopic antireflux surgery 
achieved a better quality of life improvement than those patients with BE. The authors 
compared QoL data of both groups to the mean value of general population. This means 
that laparoscopic antireflux surgery is able to improve QoL significantly in all GERD 
patients, with and without BE. 
In Conclusion, surgical treatment is able only to control acid and biliopancreatic refluxate, 
with an improvement of quality of life. A very important point of view is the efficacy of 
antireflux barrier, infact after surgical treatment, there is also still progression of disease 
although the risk seems to become very small when this treatment is successful. 
The complexity of assessment and management of CLE require a multidisciplinary 
approach, in regard of diagnosis and strategies of treatment. This is particularly true for 
surgical therapy, which has to be effective and long lasting; therefore, it should be 
preferably performed by experienced surgical teams. 
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8. Quality of life after antireflux surgery 
The large success of laparoscopic surgery as an effective treatment of gastroesophageal 
reflux disease, has established minimal invasive surgery as the gold standard in surgical 
treatment of this condition. Among antireflux procedures, laparoscopic total fundoplication 
is the most commonly used, providing excellent symptom relief (Watson et al 1996). 
Antireflux surgery has been shown to improve not only symptoms, but also quality-of life 
(QoL)  (Velanovich et 1999; Trus et al 1999). 
Laparoscopic Nissen fundoplication constructs an antireflux barrier in the cardia region and 
effectively controls the typical symptoms of gastroesophageal reflux disease in 
approximately 85-90% (Bammer et al 2001; Beldi et al 2002; Eubancs et 2000; Carlson et al 
2001) of cases at 5 to 10 years follow-up and has low morbidity and mortality rates. 
Poor surgical results are caused by mechanical problems or persistence of symptoms 
(Campos et al 1999; Rice et al 2000). 
A proportion of patients have persistent reflux symptoms and require use of proton pump 
inhibitors despite normal functional studies (Eubancs et al 2000; Khajanchee et al 2002; 
Galvani et al 2003). 
In our study only 5.9% required PPI post-operatively and the satisfaction rate was 63.8% at 6 
months and 83.3% at 12 months, with a Johnson&DeMeester  score of 8.05 (IQR: 6.95-10.20) 
at 6 months and to 7.60 (IQR: 7.60-9.50) at the 12 months follow-up. 
After antireflux surgery we observed a significant reduction in both severity and frequency 
scores of heartburn, epigastric pain, regurgitation, and respiratory symptoms, but an 
increase of dysphagia for solids and/or liquids. This point of view may affect the 
improvement of quality of life after Nissen-Rossetti fundoplication. The dysphagia was 
reported especially during the first 3 postoperative months, and in most cases it could be 
controlled by diet modifications as it gradually subsided (Loustarinen et al 2001; Mungan et 
al 1999; Balci et al 2007). 
In our series we observed 19.4% of dysphagia for solids and/or liquids at 1 months 
postoperatively and only 2 readmissions, with need for endoscopic ballon dilatation in one 
case, but at 3 months all symptoms had disappeared.  
Trus et al reported a significant and durable improvement in all 8 scales of the SF-36 at 6 
weeks and 1 year after laparoscopic antireflux surgery (Trus et al 1999). 
Amato et al reported that dysphagia for solids and/or liquids was the only significant 
symptom associated with 3 of 8 scales (physical function, role physical and bodily pain) 
(Amato et al 2008). A border line association was found between bloating and other 3 of 8 
scales (social function, role-emotional and mental health). 
Peters et al found no improvement in all 8 scales, with the exception of bodily pain, in 46 
patients at a median of 21 months after laparoscopic Nissen fundoplication (Peters et al 
1998).  
In our series we observed good results of surgical procedures with a DeMeester score after 6 
months like 8.05 and after 12 months 7,60 (p< 0.0001) and an improvement of quality of life 
measured in all subdomains of SF-36  at 6 months and 12 months. 
In our series, also, we evaluated the impact of Nissen-Rossetti fundoplication with GERD-
HRQL to measure the relation between symptoms and the quality of life of patients before 
and after surgery. 
Balci et al measured QoL with SF-36 and GERD-HRQL in 60 patients at 1 months and 6 
months which showed that QoL increased significantly for all their patients after surgery 
(Balci et al 2007).  
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In all subdomains of the SF-36 the patients score increased, showing an improved quality of 
life in the related aspects of each item and the GERD-HRQL score showed a corresponding 
increase. 
In another study Velanovich compared SF-36 and GERD-HRQL (Velanovich 1998). In that 
study, multivariate analysis showed that the only significant predictor of patient satisfaction 
was GERD-HRQL. 
Several studies have suggested an influence of psychopathological disorders on the results 
of laparoscopic fundoplication (Watson et al 1997; Velanovich 2006). Kamolz et al compared 
the postoperative results of laparoscopic fundoplication in 21 patients with anxiety 
disorders diagnosed with the International Classification of Diseases 10 (ICD-1) and 21 
controls. Although patients with anxiety disorders showed improvements in both their 
clinical parameters and the postoperative quality of life using the GIQLI questionnaire, such 
improvements were lower than those seen in control subjects. However, authors stated that 
these patients should not be excluded from surgery, and that an improvement in panic 
attacks was seen in one-third of them (Kamolz et al 2001). 
These same authors conducted a similar case–control study on 38 patients diagnosed with 
major depression according to the ICD-10 classification and found that, despite adequate 
preoperative selection and normalization of functional parameters, these patients showed 
less symptomatic relief and poorer results in the postoperative GIQLI quality-of-life 
questionnaire as compared with control cases (Kamolz et al 2003). The same group 
documented improvement of results and quality of life in patients undergoing surgery for 
GERD with stress-related symptoms depending on whether or not they had also received 
psychological therapy (Kamolz et al 2001). 
In our study all patients after surgery presented an improvement in quality of life measured 
by GERD-HRQL, with 25 (IQR 10-35.5) preoperatively, and 7 (IQR 3.5-10.15) at 6 months, 
and  5 (IQR 2.5-9.5) at 12 months. 
In conclusion laparoscopic Nissen-Rossetti fundoplication is a safe and effective surgical 
procedure for treatment of GERD, generally offering an improvement of quality of life. 
Finally, all patients of this series experienced an improvement in their postoperative quality 
of life. 
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